The "Antibody Drug Conjugates Market Report 2025-2035" has been added to ResearchAndMarkets.com's offering.World revenue for the Antibody Drug Conjugates Market is set to surpass US$16 billion in 2025 ...

Innovent Biologics, a biopharmaceutical company based in Shuzou, China, has agreed a collaboration with Roche to develop ...

A recent study has introduced a novel class of antibody-drug conjugates (ADCs) targeting trophoblast cell surface antigen 2 (TROP2), a protein overexpressed in pancreatic ductal adenocarcinoma (PDAC), ...

Creative Diagnostics, a leading manufacturer and supplier of antibodies, small molecule conjugates and critical assay ...

CSPC Pharmaceutical Group Ltd.’s antibody-drug conjugate SYS-6045 has been granted clearance by China’s National Medical Products Administration (NMPA) to enter clinical trials in China for advanced ...

The FDA’s approval of Amgen’s DLL3 × CD3 bispecific antibody tarlatamab (Imdelltra) last year validated the DLL3 cancer target, demonstrating its approvability in extensive-stage small-cell ...

Biohaven Ltd. (BHVN) and Merus N.V. (MRUS) announced a research collaboration and licensing agreement aimed at co-developing three ...

The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody with the cytotoxicity of a potent small molecule drug, ADCs can ...

Bispecific antibodies (BsAbs) are a major advancement in therapeutic oncology and hematology, capable of simultaneously engaging two distinct targets. This ...

The month of December 2024 saw a variety of biotech deals take place to advance therapies across different stages in ...

New research shows that undernourished children have reduced immunity despite full vaccination. Poor nutrition lowers ...

The Trojan horse All three of the studies Verma mentioned involved antibody-drug conjugates (ADCs), a treatment modality that’s now about a decade old but still ripe for innovation.